9.5 Sleep-Disordered Breathing in Cardiac Patients

Why Sleep-Disordered Breathing Is a Cardiac Diagnosis

Test-plan item II.A.5 is placed under non-cardiovascular conditions, but on CMC it is asked as a cardiac question: sleep-disordered breathing is one of the most prevalent, most under-recognized and most modifiable contributors to resistant hypertension, atrial fibrillation recurrence, nocturnal bradyarrhythmia, pulmonary hypertension and heart failure decompensation. Roughly half of patients with heart failure have clinically significant sleep-disordered breathing, and the majority of them have never been tested.

Definitions and Severity

• Apnea: cessation of airflow for 10 seconds or longer.
• Hypopnea: a reduction in airflow of 30% or more for 10 seconds or longer with an associated desaturation (3-4%, depending on scoring rules) or arousal.
• Apnea-Hypopnea Index (AHI): events per hour of sleep. Normal under 5; mild 5-14.9; moderate 15-29.9; severe 30 or more.

The Three Patterns

How OSA Damages the Cardiovascular System

Five mechanisms, all testable:

1. Intrathoracic pressure swings. Inspiratory effort against a closed airway (a repeated Muller maneuver) generates intrathoracic pressures of -40 to -80 cmH2O. This raises LV transmural pressure and therefore LV afterload, increases venous return to the right heart, shifts the septum leftward, and stretches the atria. Repeated atrial stretch is a direct driver of atrial remodeling and atrial fibrillation.
2. Intermittent hypoxemia and reoxygenation produce oxidative stress, reduced nitric oxide bioavailability, endothelial dysfunction and accelerated atherosclerosis — a pattern more injurious than sustained hypoxemia.
3. Sympathetic surges at each arousal cause nocturnal blood pressure spikes, a non-dipping or reverse-dipping 24-hour pattern, an exaggerated morning surge, and elevated daytime catecholamines. OSA is the single most common identifiable cause of resistant hypertension, present in roughly 70-80% of patients with resistant hypertension.
4. Systemic inflammation and metabolic dysregulation — elevated CRP and IL-6, insulin resistance, and worsened glycemic control.
5. Hypoxia-triggered vagal surges (the diving reflex) produce nocturnal sinus pauses and high-grade AV block that resolve with CPAP. This is a classic exam item: nocturnal bradyarrhythmias in a snoring, obese patient warrant evaluation for OSA before a permanent pacemaker is implanted.

Downstream consequences that show up on the CMC exam: atrial fibrillation recurrence after cardioversion is roughly double in untreated OSA compared with treated patients, catheter ablation success is meaningfully lower with untreated OSA and improves with CPAP, and OSA contributes to Group 3 pulmonary hypertension, worse heart failure outcomes, stroke, and increased perioperative complications.

Central Sleep Apnea in Heart Failure and the ASV Safety Rule

In HFrEF, Cheyne-Stokes respiration arises from high loop gain: chemoreceptor sensitivity to CO2 is increased, and the prolonged circulation time of a low-output state delays the feedback signal so that ventilation overshoots and undershoots. The patient hyperventilates, drives PaCO2 below the apneic threshold, stops breathing, accumulates CO2, and hyperventilates again. The long cycle length — 60 seconds or more — is a direct reflection of the circulation time and worsens as the heart failure worsens.

The SERVE-HF Rule

Adaptive servo-ventilation (ASV) is contraindicated in patients with symptomatic heart failure with reduced ejection fraction and an ejection fraction of 45% or less who have predominantly central sleep apnea.

The SERVE-HF trial randomized these exact patients (EF 45% or less, AHI 15 or greater with more than 50% central events) to ASV added to guideline-directed therapy, and found no benefit on the primary outcome plus a significant increase in all-cause mortality (hazard ratio about 1.28) and cardiovascular mortality (hazard ratio about 1.34). This produced a field safety notice and a change in labeling. It is one of the highest-yield safety facts in this section.

What the rule does not say:

• It does not ban CPAP in heart failure. CPAP remains first-line for obstructive sleep apnea in patients with heart failure; the CANPAP trial of CPAP for central apnea in HFrEF was neutral overall, not harmful.
• It does not apply to patients with an EF above 45%, to treatment-emergent (complex) central apnea, or to opioid-associated central apnea, where ASV remains an option.
• It does not mean central apnea should be ignored. Optimizing heart failure therapy is the treatment — guideline-directed medical therapy, decongestion, cardiac resynchronization where indicated, and correction of the low-output state frequently reduce or abolish Cheyne-Stokes respiration.

Other options for central apnea include nocturnal supplemental oxygen and transvenous phrenic nerve stimulation, which is FDA-approved for moderate-to-severe central sleep apnea in adults. The implanted device resembles a pacemaker generator with a lead placed in a pericardiophrenic or left brachiocephalic vein and is programmed to be active during sleeping hours. Nurses caring for these patients should know it is not a pacemaker, does not treat arrhythmias, and has its own interrogation and magnet behavior.

Screening, Diagnosis and Treatment

Screening Tools

• STOP-BANG: Snoring, Tiredness, Observed apneas, blood Pressure (hypertension), BMI above 35, Age above 50, Neck circumference above 40 cm, Gender male. Score 0-2 low risk, 3-4 intermediate, 5-8 high risk, with excellent sensitivity for moderate-to-severe OSA. This is the practical bedside tool.
• Epworth Sleepiness Scale: a score of 11 or higher indicates excessive daytime sleepiness. Important caveat: many cardiac patients with significant OSA are not sleepy, and Epworth performs poorly as a screen in heart failure. A normal Epworth score does not exclude OSA.
• Berlin Questionnaire is an alternative multi-domain screen.

Diagnostic Testing

Attended in-laboratory polysomnography is the reference standard and is the appropriate test whenever central apnea, hypoventilation, significant cardiopulmonary disease, neuromuscular disease or opioid use is suspected — which describes most cardiac inpatients. Home sleep apnea testing is acceptable only for uncomplicated suspected moderate-to-severe OSA; it uses recording time rather than measured sleep time, which systematically underestimates the AHI, and it cannot reliably distinguish central from obstructive events. A negative home study in a high-probability patient must be followed by polysomnography.

Treatment of OSA

• CPAP is first-line, usually titrated between 5 and 20 cmH2O. Auto-titrating PAP is acceptable in uncomplicated OSA but not in heart failure, central apnea or hypoventilation, where a fixed, titrated pressure is required.
• Adherence is the entire therapeutic effect. The standard adherence definition used by payers is 4 hours or more per night on at least 70% of nights during a consecutive 30-day period within the first 90 days. CPAP lowers blood pressure by an average of only 2-3 mmHg across trial populations, but far more in resistant hypertension and in good adherers; the neutral cardiovascular outcome trials (SAVE, RICCADSA) were limited by average use of only about 3.3 hours per night. Adherence coaching is therefore a genuine cardiovascular intervention.
• Bilevel PAP for CPAP intolerance, high pressure requirements, or coexisting hypoventilation such as obesity hypoventilation syndrome.
• Oral appliances (mandibular advancement devices) for mild-to-moderate OSA or CPAP refusal.
• Positional therapy for supine-predominant disease.
• Weight management: about a 10% weight loss reduces the AHI by roughly a quarter; bariatric surgery produces larger reductions; tirzepatide is now FDA-approved for moderate-to-severe OSA with obesity.
• Hypoglossal nerve stimulation for moderate-to-severe OSA with CPAP failure in selected patients (BMI limits, and absence of complete concentric palatal collapse on drug-induced sleep endoscopy). The patient activates it with a handheld remote at bedtime; it has MRI conditionality that must be verified before imaging.
• Behavioral measures: avoid alcohol and sedative-hypnotics near bedtime, treat nasal congestion, and address smoking.

Perioperative, Procedural and Sedation Risk

Known or suspected OSA increases post-operative hypoxemia, unplanned ICU transfer, reintubation, atrial fibrillation, delirium and cardiac events. In cardiac care this surfaces during transesophageal echocardiography sedation, cardioversion, cath-lab conscious sedation, electrophysiology procedures, and the first post-operative nights after CABG, valve surgery or TAVR.

Practical nursing rules:

• Screen before you sedate. Complete a STOP-BANG on every patient scheduled for procedural sedation; treat a score of 5 or higher as OSA until proven otherwise and plan accordingly.
• Respect the drug interaction with the arousal response. Opioids and benzodiazepines blunt the arousal that terminates each apneic event, and their combination is far worse than either alone. Risk is highest in the first 24 hours and during the rapid-eye-movement rebound that occurs on post-operative nights 2 and 3. Use multimodal analgesia — scheduled acetaminophen, NSAIDs where renal function and bleeding risk allow, regional and local techniques, and dexmedetomidine, which provides sedation with relatively preserved respiratory drive. Avoid basal-rate patient-controlled analgesia in OSA.
• Monitor continuously, not intermittently. Continuous pulse oximetry, with capnography when opioids are given by continuous infusion or the patient is moderately to deeply sedated. Spot-check oximetry misses the cyclic desaturation pattern entirely.
• Do not treat OSA desaturation with oxygen alone. Supplemental oxygen raises the SpO2 nadir and silences the monitor while apneas, arousals and CO2 retention continue unabated. The correct response is to restore upper-airway patency with PAP and reduce the respiratory depressants.
• Continue home PAP in the hospital. Have the patient bring their own device and mask, verify the prescribed settings, and apply it whenever the patient sleeps, including daytime naps, starting immediately after extubation or procedural recovery. If the home device is unavailable, obtain hospital equipment with a matched pressure — and remember that auto-PAP is not an acceptable substitute in heart failure or central apnea.
• Position and extubate deliberately. Non-supine positioning where possible, head of bed elevated 30-45 degrees or reverse Trendelenburg, and extubation awake and upright.
• Interpret the monitor correctly. Cyclical dips of 4-10% with spontaneous recovery, occurring only when the patient is asleep and unstimulated, are the signature of obstructive apnea — not a poorly placed probe.

The Nursing Role

• Opportunistic screening. Screen every cardiac patient with resistant hypertension, atrial fibrillation (especially recurrence after cardioversion or ablation), HFrEF or HFpEF, nocturnal angina, unexplained nocturnal bradyarrhythmias, pulmonary hypertension, or obesity. Nurses see the sleeping patient; physicians usually do not.
• Document what you observe. Witnessed apneas, loud snoring with gasping arousals, the pattern and depth of nocturnal desaturation, and any bradyarrhythmia that occurs only during sleep. This documentation is frequently what triggers the sleep referral.
• Support titration and troubleshoot the interface. Mask leak and nasal-bridge pressure injury (refit, use a gel spacer or a prophylactic dressing, consider nasal pillows); dry mouth and nasal congestion (heated humidification, chin strap, saline); claustrophobia (desensitization, smaller interface, ramp feature); aerophagia and gastric distension (reassess pressure and ramp); and residual events on the device download.
• Teach the truth about the therapy. PAP is a treatment, not a cure — benefit reverses within nights of stopping. Reinforce nightly, all-night use; address drowsy-driving safety; and discuss weight, alcohol and sedative avoidance without moralizing.
• Coordinate follow-up. Ensure a sleep-medicine appointment with a device download and residual AHI, and link it to heart failure and arrhythmia clinic follow-up so that OSA treatment is not managed in isolation from the cardiac plan it exists to improve.